Trial Radar
Sign in

NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs

NCT06930625

RecruitingPhase 3

Sponsor: Debiopharm International SA

Conditions: Acromegaly

Interventions: Debio 4126, Placebo

Countries: United States, Austria, Belgium, Brazil, Bulgaria, Denmark, Estonia, France

The primary purpose of this study is to assess the effect of Debio 4126 in the maintenance of the levels of insulin-like growth factor 1 (IGF-1) ≤1x upper limit of normal (ULN) in the double-blind period (Period 1) in comparison to placebo at week 36.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria
Inclusion criteria

1. Patients ≥18 years of age
2. Patients who are receiving octreotide or lanreotide monotherapy for acromegaly for at least 6 months, at a stable dose for the last 12 weeks.
3. IGF-1 at screening ≤1x ULN
4. Acromegaly diagnosis, defined as per protocol
5. Adequate bone marrow, hepatic and renal function
6. To enter Period 2 (Arms A and B): IGF-1 ≤1x ULN at Week 34, or up to Week 48 when treated with rescue medication
7. Other protocol-defined criteria apply

Exclusion criteria

1. Compression of optic chiasm causing visual defects
2. Symptomatic cholelithiasis or bile duct dilatation
3. Planned cholecystectomy during the trial duration
4. Acute or chronic pancreatitis
5. Pituitary radiotherapy
6. Uncontrolled hypothyroidism
7. Uncontrolled diabetes
8. Pituitary surgery within 6 months before screening or planned on trial
9. Treatment with pasireotide within 6 months prior to screening, pegvisomant or dopamine agonists within 3 months prior to screening
10. Recent or ongoing cardiovascular or thromboembolic diseases including heart failure, myocardial infarction, stroke, certain arrythmias, pulmonary embolism
11. Other protocol-defined criteria apply
Locations (72)
  • Los Angeles, California, United States
  • Chicago, Illinois, United States
  • Boston, Massachusetts, United States
  • St Louis, Missouri, United States
  • Las Vegas, Nevada, United States
  • New York, New York, United States
  • Cleveland, Ohio, United States
  • Columbus, Ohio, United States
  • Portland, Oregon, United States
  • Philadelphia, Pennsylvania, United States
  • Graz, Austria
  • Vienna, Austria
  • Ghent, Belgium
  • Curitiba, Brazil
  • Fortaleza, Brazil
  • Minas Gerais, Brazil
  • Rio de Janeiro, Brazil
  • São Paulo, Brazil
  • Sofia, Bulgaria
  • Copenhagen, Denmark
  • Køge, Denmark
  • Tallinn, Estonia
  • Tallinn, Estonia
  • Angers, France
  • Bron, France
  • Le Kremlin-Bicêtre, France
  • Marseille, France
  • Pessac, France
  • Toulouse, France
  • Berlin, Germany
  • + 42 more on CT.gov